Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Positive data for CombinatoRx arthritis drug
The study met its primary endpoint of improvement in the Auscan visual analogue pain scale, a standardized measure of pain. The data show that there was a statistically
The study met its primary endpoint of improvement in the Auscan visual analogue pain scale, a standardized measure of pain. The data show that there was a statistically
The collaboration with Merck combines Rigel’s capabilities in ubiquitin ligases with Merck’s molecular profiling technology and downstream clinical infrastructure to explore this promising new class of drug targets.
Xibrom, a topical, twice-daily, non-steroidal anti-inflammatory solution, was originally approved by the FDA in March 2005 for the treatment of ocular inflammation following cataract surgery. “Since Xibrom’s launch,
The focus of the proposed phase III program will be to develop denufosol for cystic fibrosis (CF) as an early intervention therapy for treatment of patients with mild
The company says its new application provides additional clinical data showing that Neurodex, a combination of dextromethorphan and quinidine, is safe and effective in reducing the frequency and
Cetrorelix is the company’s lead candidate for the benign prostate hyperplasia indication, and while Aeterna intends to pursue the late-stage clinical development of cetrorelix, Solvay will pursue its
The company has said that objective results from an independent radiology organization concluded the treatment resulted in an overall clinical benefit of 85%. Adventrx also reported longer than
The randomized, double-blind, placebo-controlled trial has been conducted at 67 oncology centers across the U.S. The trial has enrolled both treatment-naive and relapsed/refractory patients with stable or responding
The agency has recommended Remicade for the treatment of moderate to severe ulcerative colitis in patients who have had little success with conventional therapies. Ulcerative colitis is an
The decision by the US regulators comes shortly after the treatment was approved in Europe. Exubera was found in clinical trials to be as effective as short-acting insulin